UNITED THERAPEUTICS Corp UTHR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
7/9
Piotroski F — financial health
16.93
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.2B | $1.3B | $2.8B | $1.0B | $7.1B |
| 2024 | $2.9B | $1.2B | $2.6B | $1.1B | $6.4B |
| 2023 | $2.3B | $984.8M | $2.1B | $747.6M | $6.0B |
| 2022 | $1.9B | $727.3M | $1.8B | $663.7M | $4.8B |
| 2021 | $1.7B | $475.8M | $1.6B | $477.4M | $4.0B |
| 2020 | $1.5B | — | $1.4B | $696.4M | $3.4B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO | 2026-06-25 | Sell | 684 | $543.54 |
| ROTHBLATT MARTINE A | Chairperson & CEO | 2026-06-25 | Sell | 418 | $545.08 |
| ROTHBLATT MARTINE A | Chairperson & CEO | 2026-06-25 | Sell | 301 | $546.38 |
| ROTHBLATT MARTINE A | Chairperson & CEO | 2026-06-25 | Sell | 441 | $547.87 |
| ROTHBLATT MARTINE A | Chairperson & CEO | 2026-06-25 | Sell | 645 | $548.77 |
| ROTHBLATT MARTINE A | Chairperson & CEO | 2026-06-25 | Sell | 762 | $549.55 |
| ROTHBLATT MARTINE A | Chairperson & CEO | 2026-06-25 | Sell | 1,617 | $550.86 |
| ROTHBLATT MARTINE A | Chairperson & CEO | 2026-06-25 | Option exercise | 9,500 | $135.42 |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 16.93 (safe)
- Working capital / assets 0.399
- Retained earnings / assets 1.086
- EBIT / assets 0.189
- Equity / liabilities 9.054
Source: SEC EDGAR filings · CIK 0001082554 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.